ChainCatcher message, according to market data, the US stock BNB Treasury Company Windtree Therapeutics (WINT) received a notification from Nasdaq in 2025 for staying below $1 for too long (Rule 5550(a)(2)). After multiple reverse splits and not meeting the usual grace period, its common stock will be delisted from the Nasdaq Capital Market on August 21 and will trade on the OTC market. This news caused its stock price to start falling early this morning, ultimately closing down 77.21%, with a market capitalization of only $3.152 million.
It is noteworthy that WINT's stock price has maintained a textbook standard 'zeroing out' trend for nearly a year. On August 22 last year, the stock price was $517.5, and it has since accumulated a decline of 99.98%. The opening price on February 21 of this year was $4.68, and it has since accumulated a decline of 97.8%. After announcing the BNB Treasury strategy a month ago, the stock experienced a significant increase in trading volume over several trading days (including several days before the announcement), ultimately reaching a recent high of $1.28 on July 18, before starting a unilateral downward trend again, with an accumulation decline of 91.4% to date.
It is reported that Windtree Therapeutics is a clinical-stage biopharmaceutical and medical device company, with multiple medical projects still in clinical stages far from commercialization. According to the latest data, the company's net income for the most recent quarter was -$10.64 million, compared to -$4.04 million in the previous quarter, with losses widening by 163.04%. The company initially announced the launch of the BNB Treasury strategy on July 16, raising $60 million through a securities subscription. On July 25, it announced that it had signed a new financing agreement worth $520 million to buy BNB.
